Skip to main content
. 2020 Feb 11;2020:7821913. doi: 10.1155/2020/7821913

Table 6.

In vivo efficacy of MEFTN in tumor xenograft models.

Groups Ovarian (PA1) Lung (A549)
Tumor size (mm3) after the treatment period
Untreated 354 ± 7.1 426 ± 60
MEFTN 89 ± 15 170 ± 43

Xenograft models were generated in nude mice. MEFTN (300 mg/kg BW p.o. BID) was fed orally in treated groups, and vehicle was fed to the untreated group for 31 days in ovarian and 14 days in lung cancer. Mean ± SD was indicated in the result.